The recent policy initiatives taken by the government of India will boost Indian Pharma and healthcare sectors in the long run says a report by Centrum post a three-day roadshow with pharma and healthcare experts.
Government initiatives like production-linked incentive (PLI) schemes to boost domestic manufacturing and ensure resilience from external shocks.
Bulk drug parks to promote the domestic production of essential drugs and Promotion of Research & Innovation in the Pharma and MedTech sector (PRIP) scheme along with the promotion of AYUSH as an alternative therapy.
The PLI scheme will ensure greater resilience to external shocks, enforce greater drug security and boost the capacity for domestic production of critical bulk drugs and high-value products. The three supporting schemes announced by the government will incentivise Indian and global players to enhance investment and production in the critical bulk drugs and high-value product sectors. Read more
Source: Economic Times